---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-090872"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-09-24T23:59:59+00:00"
generated_at: "2026-05-17T05:48:57.524693+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics: Phase 2 stenoparib shows median overall survival >25 months for platinum-resistant ovarian cancer

## Summary
- Median overall survival (mOS) now exceeds 25 months, not yet formally reached, in ongoing Phase 2 trial.
- Two patients remain on therapy >24 months; one with BRCA wild-type shows benefit, typically precluded by PARP inhibitors.
- Data presented at AACR 2025 Ovarian Cancer Conference; FDA draft guidance supports OS as endpoint for approval.
- Stenoparib shows less myelotoxicity vs earlier PARP inhibitors, relevant after 2022 market withdrawal of some PARP inhibitors.

## SEC filing metadata
- accession: 0001213900-25-090872
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390025090872/0001213900-25-090872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390025090872/ea0258492-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-090872
- JSON: https://secwatch.observer/filing/0001213900-25-090872.json
- Plain text: https://secwatch.observer/filing/0001213900-25-090872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.